Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
Journal of Medical Case Reports, 04/24/2012Michalaki V et al.
The authors present the case of a 43–year–old Caucasian man with advanced chromophobe renal cell carcinoma treated with the tyrosine kinase inhibitor sunitinib and subsequently with sorafenib and the mammalian target of the rapamycin inhibitor everolimus, achieving a prolonged response and significant clinical benefit. The authors report an unexpectedly high efficacy of everolimus as a third–line treatment in a patient with metastatic chromophobe renal cell carcinoma.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.